These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 36165733)

  • 41. Modifying and Evaluating the Opioid Overdose Knowledge Scale for Prescription Opioids: A Pilot Study of the Rx-OOKS.
    Shoup JA; Mueller SR; Binswanger IA; Williams AV; Strang J; Glanz JM
    Pain Med; 2020 Oct; 21(10):2244-2252. PubMed ID: 32827044
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacy leaders' beliefs about how pharmacies can support a sustainable approach to providing naloxone to the community.
    Donovan E; Bratberg J; Baird J; Burstein D; Case P; Walley AY; Green TC
    Res Social Adm Pharm; 2020 Oct; 16(10):1493-1497. PubMed ID: 31983625
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Public Health and Pharmacy Partnerships in Opioid Harm Reduction: Responding to Community Needs.
    Medina S; Tomaszewski R; Chhen S; Hanson A; Mueller A; Palombi LC
    Prog Community Health Partnersh; 2021; 15(1):37-46. PubMed ID: 33775959
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of a publicly funded pharmacy-dispensed naloxone program on fatal opioid overdose rates: A population-based study.
    Antoniou T; Men S; Tadrous M; Leece P; Munro C; Gomes T
    Drug Alcohol Depend; 2022 Jul; 236():109473. PubMed ID: 35523113
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of naloxone furnishing community pharmacies in San Francisco.
    Nguyen AM; Kearney TE; Apollonio DE
    J Am Pharm Assoc (2003); 2020; 60(6):1050-1057.e1. PubMed ID: 32948461
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Naloxone accessibility without an outside prescription from U.S. community pharmacies: A systematic review.
    Lai RK; Friedson KE; Reveles KR; Bhakta K; Gonzales G; Hill LG; Evoy KE
    J Am Pharm Assoc (2003); 2022; 62(6):1725-1740. PubMed ID: 35989151
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Implementation of academic detailing for pharmacists on opioid use disorder and harm reduction.
    DiPaula BA; Cooke CE; Boyle CJ; Love RC
    J Am Pharm Assoc (2003); 2022; 62(1):241-246. PubMed ID: 34690080
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Feasibility and acceptability of a proposed pharmacy-based harm reduction intervention to reduce opioid overdose, HIV and hepatitis C.
    Meyerson BE; Agley JD; Jayawardene W; Eldridge LA; Arora P; Smith C; Vadiei N; Kennedy A; Moehling T;
    Res Social Adm Pharm; 2020 May; 16(5):699-709. PubMed ID: 31611071
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacy Naloxone Standing Order and Community Opioid Fatality Rates Over Time.
    Xuan Z; Walley AY; Yan S; Chatterjee A; Green TG; Pollini RA
    JAMA Netw Open; 2024 Aug; 7(8):e2427236. PubMed ID: 39207758
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identifying barriers to dispensing naloxone: A survey of community pharmacists in North Carolina.
    Rudolph SE; Branham AR; Rhodes LA; Hayes HH; Moose JS; Marciniak MW
    J Am Pharm Assoc (2003); 2018; 58(4S):S55-S58.e3. PubMed ID: 30006187
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Preliminary effectiveness of online opioid overdose and naloxone administration training and impact of naloxone possession on opioid use.
    Sisson ML; Azuero A; Chichester KR; Carpenter MJ; Businelle MS; Shelton RC; Cropsey KL
    Drug Alcohol Depend; 2023 Aug; 249():110815. PubMed ID: 37336007
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Primary Care Patient Experience with Naloxone Prescription.
    Behar E; Rowe C; Santos GM; Murphy S; Coffin PO
    Ann Fam Med; 2016 Sep; 14(5):431-6. PubMed ID: 27621159
    [TBL] [Abstract][Full Text] [Related]  

  • 53. "They're not doing enough.": women's experiences with opioids and naloxone in Toronto.
    Macleod ER; Tajbakhsh I; Hamilton-Wright S; Laliberte N; Wiese JL; Matheson FI
    Subst Abuse Treat Prev Policy; 2021 Mar; 16(1):26. PubMed ID: 33743756
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Expert views on state-level naloxone access laws: a qualitative analysis of an online modified-Delphi process.
    Grant S; Smart R
    Harm Reduct J; 2022 Jun; 19(1):64. PubMed ID: 35676719
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term effects of opioid overdose prevention and response training on medical student knowledge and attitudes toward opioid overdose: A pilot study.
    Moses TEH; Chou JS; Moreno JL; Lundahl LH; Waineo E; Greenwald MK
    Addict Behav; 2022 Mar; 126():107172. PubMed ID: 34774365
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Estimating Centre for Disease Control and Prevention-defined overdose risk in people prescribed opioids for chronic non-cancer pain: implications for take-home naloxone provision.
    Lintzeris N; Santo T; Nielsen S; Degenhardt L; Campbell G
    Intern Med J; 2019 Aug; 49(8):1054-1055. PubMed ID: 31387142
    [No Abstract]   [Full Text] [Related]  

  • 57. Racial inequities in U.S. naloxone prescriptions.
    Madden EF; Qeadan F
    Subst Abus; 2020; 41(2):232-244. PubMed ID: 31718487
    [No Abstract]   [Full Text] [Related]  

  • 58. Stigma by Association: To what Extent is the Attitude Toward Naloxone Affected by the Stigma of Opioid Use Disorder?
    Adeosun SO
    J Pharm Pract; 2023 Aug; 36(4):941-952. PubMed ID: 35505618
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of a Program to Screen Patients in Community Pharmacies for Opioid Misuse and Accidental Overdose.
    Skoy E; Frenzel O; Eukel H; Lothspeich E; Steig J; Strand M; Werremeyer A
    Prev Chronic Dis; 2022 Jul; 19():E41. PubMed ID: 35834737
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Non-fatal opioid overdose, naloxone access, and naloxone training among people who recently used opioids or received opioid agonist treatment in Australia: The ETHOS Engage study.
    Conway A; Valerio H; Peacock A; Degenhardt L; Hayllar J; Harrod ME; Henderson C; Read P; Gilliver R; Christmass M; Dunlop A; Montebello M; Whitton G; Reid D; Lam T; Alavi M; Silk D; Marshall AD; Treloar C; Dore GJ; Grebely J;
    Int J Drug Policy; 2021 Oct; 96():103421. PubMed ID: 34452808
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.